Home > Haematology > ASH 2021 > Acute Lymphoblastic Leukaemia > UKALL 2003: Therapy de-escalation safe in low-risk MRD patients with ALL

UKALL 2003: Therapy de-escalation safe in low-risk MRD patients with ALL

Presented By
Dr Sujith Samarasinghe, Great Ormond Street Hospital, UK
Conference
ASH 2021
Trial
UKALL 2003
Doi
https://doi.org/10.55788/ce125c0a
Therapy de-escalation in patients with acute lymphoblastic leukaemia (ALL) and a low-risk measurable residual disease (MRD) profile is safe, 10-year follow-up results of the UKALL 2003 trial showed. Patients with a high-risk MRD profile continued to benefit from augmented therapy compared with standard therapy, especially high-risk genetic subgroups and patients with B-cell precursor (BCP) disease [1]. The UKALL 2003 trial (NCT00222612) was designed to evaluate the effects of de-escalation of therapy in patients with ALL and a low-risk MRD profile, and treatment intensification in patients with ALL and a high-risk MRD profile. Participants in the low-risk MRD group were randomised to 1 (n=261) or 2 (n=260) delayed intensifications (DIs) of therapy. High-risk patients were randomised to standard therapy (n=266) or augmented therapy (n=267). Dr Sujith Samarasinghe (G...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on